1
|
Uzal-Varela R, Rodríguez-Rodríguez A, Lalli D, Valencia L, Maneiro M, Botta M, Iglesias E, Esteban-Gómez D, Angelovski G, Platas-Iglesias C. Endeavor toward Redox-Responsive Transition Metal Contrast Agents Based on the Cross-Bridge Cyclam Platform. Inorg Chem 2024; 63:1575-1588. [PMID: 38198518 PMCID: PMC10806912 DOI: 10.1021/acs.inorgchem.3c03486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 12/21/2023] [Accepted: 12/21/2023] [Indexed: 01/12/2024]
Abstract
We present the synthesis and characterization of a series of Mn(III), Co(III), and Ni(II) complexes with cross-bridge cyclam derivatives (CB-cyclam = 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane) containing acetamide or acetic acid pendant arms. The X-ray structures of [Ni(CB-TE2AM)]Cl2·2H2O and [Mn(CB-TE1AM)(OH)](PF6)2 evidence the octahedral coordination of the ligands around the Ni(II) and Mn(III) metal ions, with a terminal hydroxide ligand being coordinated to Mn(III). Cyclic voltammetry studies on solutions of the [Mn(CB-TE1AM)(OH)]2+ and [Mn(CB-TE1A)(OH)]+ complexes (0.15 M NaCl) show an intricate redox behavior with waves due to the MnIII/MnIV and MnII/MnIII pairs. The Co(III) and Ni(II) complexes with CB-TE2A and CB-TE2AM show quasi-reversible features due to the CoIII/CoII or NiII/NiIII pairs. The [Co(CB-TE2AM)]3+ complex is readily reduced by dithionite in aqueous solution, as evidenced by 1H NMR studies, but does not react with ascorbate. The [Mn(CB-TE1A)(OH)]+ complex is however reduced very quickly by ascorbate following a simple kinetic scheme (k0 = k1[AH-], where [AH-] is the ascorbate concentration and k1 = 628 ± 7 M-1 s-1). The reduction of the Mn(III) complex to Mn(II) by ascorbate provokes complex dissociation, as demonstrated by 1H nuclear magnetic relaxation dispersion studies. The [Ni(CB-TE2AM)]2+ complex shows significant chemical exchange saturation transfer effects upon saturation of the amide proton signals at 71 and 3 ppm with respect to the bulk water signal.
Collapse
Affiliation(s)
- Rocío Uzal-Varela
- Centro
Interdisciplinar de Química e Bioloxía (CICA) and Departamento
de Química, Facultade de Ciencias, Universidade da Coruña, A Coruña 15071, Galicia, Spain
| | - Aurora Rodríguez-Rodríguez
- Centro
Interdisciplinar de Química e Bioloxía (CICA) and Departamento
de Química, Facultade de Ciencias, Universidade da Coruña, A Coruña 15071, Galicia, Spain
| | - Daniela Lalli
- Dipartimento
di Scienze e Innovazione Tecnologica, Magnetic Resonance Platform
(PRISMA-UPO), Universitá del Piemonte
Orientale, Viale T. Michel
11, Alessandria 15121, Italy
| | - Laura Valencia
- Departamento
de Química Inorgánica, Facultad de Ciencias, Universidade de Vigo, As Lagoas, Marcosende 36310, Pontevedra, Spain
| | - Marcelino Maneiro
- Departamento
de Química Inorgánica, Facultade de Ciencias, Campus
Terra, Universidade de Santiago de Compostela, Lugo 27002, Galicia, Spain
| | - Mauro Botta
- Dipartimento
di Scienze e Innovazione Tecnologica, Magnetic Resonance Platform
(PRISMA-UPO), Universitá del Piemonte
Orientale, Viale T. Michel
11, Alessandria 15121, Italy
| | - Emilia Iglesias
- Centro
Interdisciplinar de Química e Bioloxía (CICA) and Departamento
de Química, Facultade de Ciencias, Universidade da Coruña, A Coruña 15071, Galicia, Spain
| | - David Esteban-Gómez
- Centro
Interdisciplinar de Química e Bioloxía (CICA) and Departamento
de Química, Facultade de Ciencias, Universidade da Coruña, A Coruña 15071, Galicia, Spain
| | - Goran Angelovski
- Laboratory
of Molecular and Cellular Neuroimaging, International Center for Primate
Brain Research (ICPBR), Center for Excellence in Brain Science and
Intelligence Technology (CEBSIT), Chinese
Academy of Sciences (CAS), Shanghai 201602, PR China
| | - Carlos Platas-Iglesias
- Centro
Interdisciplinar de Química e Bioloxía (CICA) and Departamento
de Química, Facultade de Ciencias, Universidade da Coruña, A Coruña 15071, Galicia, Spain
| |
Collapse
|
2
|
Ramogida C, Price E. Transition and Post-Transition Radiometals for PET Imaging and Radiotherapy. Methods Mol Biol 2024; 2729:65-101. [PMID: 38006492 DOI: 10.1007/978-1-0716-3499-8_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2023]
Abstract
Radiometals are an exciting class of radionuclides because of the large number of metallic elements available that have medically useful isotopes. To properly harness radiometals, they must be securely bound by chelators, which must be carefully matched to the radiometal ion to maximize radiolabeling performance and the stability of the resulting complex. This chapter focuses on practical aspects of radiometallation chemistry including chelator selection, radiolabeling procedures and conditions, radiolysis prevention, purification, quality control, requisite equipment and reagents, and useful tips.
Collapse
Affiliation(s)
- Caterina Ramogida
- Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
- Life Sciences Division, TRIUMF, Vancouver, BC, Canada.
| | - Eric Price
- Department of Chemistry, College of Arts and Science, University of Saskatchewan, Saskatoon, SK, Canada
| |
Collapse
|
3
|
Uzal-Varela R, Patinec V, Tripier R, Valencia L, Maneiro M, Canle M, Platas-Iglesias C, Esteban-Gómez D, Iglesias E. On the dissociation pathways of copper complexes relevant as PET imaging agents. J Inorg Biochem 2022; 236:111951. [PMID: 35963110 DOI: 10.1016/j.jinorgbio.2022.111951] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 07/15/2022] [Accepted: 07/27/2022] [Indexed: 02/07/2023]
Abstract
Several bifunctional chelators have been synthesized in the last years for the development of new 64Cu-based PET agents for in vivo imaging. When designing a metal-based PET probe, it is important to achieve high stability and kinetic inertness once the radioisotope is coordinated. Different competitive assays are commonly used to evaluate the possible dissociation mechanisms that may induce Cu(II) release in the body. Among them, acid-assisted dissociation tests or transchelation challenges employing EDTA or SOD are frequently used to evaluate both solution thermodynamics and the kinetic behavior of potential metal-based systems. Despite of this, the Cu(II)/Cu(I) bioreduction pathway that could be promoted by the presence of bioreductants still remains little explored. To fill this gap we present here a detailed spectroscopic study of the kinetic behavior of different macrocyclic Cu(II) complexes. The complexes investigated include the cross-bridge cyclam derivative [Cu(CB-TE1A)]+, whose structure was determined using single-crystal X-ray diffraction. The acid-assisted dissociation mechanism was investigated using HClO4 and HCl to analyse the effect of the counterion on the rate constants. The complexes were selected so that the effects of complex charge and coordination polyhedron could be assessed. Cyclic voltammetry experiments were conducted to investigate whether the reduction to Cu(I) falls within the window of common bioreducing agents. The most striking behavior concerns the [Cu(NO2Th)]2+ complex, a 1,4,7-triazacyclononane derivative containing two methylthiazolyl pendant arms. This complex is extremely inert with respect to dissociation following the acid-catalyzed mechanism, but dissociates rather quickly in the presence of a bioreductant like ascorbic acid.
Collapse
Affiliation(s)
- Rocío Uzal-Varela
- Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 A Coruña, Galicia, Spain
| | - Véronique Patinec
- Univ Brest, UMR-CNRS 6521 CEMCA, 6 avenue Victor le Gorgeu, 29238 Brest, France
| | - Raphaël Tripier
- Univ Brest, UMR-CNRS 6521 CEMCA, 6 avenue Victor le Gorgeu, 29238 Brest, France
| | - Laura Valencia
- Departamento de Química Inorgánica, Universidade de Vigo, Facultad de Ciencias, 36310 Pontevedra, Spain
| | - Marcelino Maneiro
- Departamento de Química Inorgánica, Universidade de Santiago de Compostela, Facultade de Ciencias, 27002 Lugo, Spain
| | - Moisés Canle
- Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 A Coruña, Galicia, Spain
| | - Carlos Platas-Iglesias
- Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 A Coruña, Galicia, Spain
| | - David Esteban-Gómez
- Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 A Coruña, Galicia, Spain.
| | - Emilia Iglesias
- Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 A Coruña, Galicia, Spain.
| |
Collapse
|
4
|
Bhise A, Park H, Lee W, Sarkar S, Ha YS, Rajkumar S, Nam B, Lim JE, Huynh PT, Lee K, Son JY, Kim JY, Lee KC, Yoo J. Preclinical Evaluation of hnRNPA2B1 Antibody in Human Triple-Negative Breast Cancer MDA-MB-231 Cells via PET Imaging. Pharmaceutics 2022; 14:pharmaceutics14081677. [PMID: 36015303 PMCID: PMC9415040 DOI: 10.3390/pharmaceutics14081677] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 07/27/2022] [Accepted: 08/09/2022] [Indexed: 11/25/2022] Open
Abstract
Triple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Because TNBC lacks the expression of commonly targeted receptors, it is challenging to develop a new imaging agent for this cancer subtype. Heterogeneous nuclear ribonucleoproteins (hnRNPs) are RNA–protein complexes that have been linked to tumor development and progression. Considering the high expression of hnRNPA2B1, an hnRNP subtype, in TNBC MDA-MB-231 cells, this study aimed to develop a novel hnRNPA2B1 antibody-based nuclear imaging agent. The hnRNPA2B1-specific antibody was radiolabeled with 64Cu and evaluated in vitro and in vivo. The trans-cyclooctene (TCO) was functionalized on the antibody to obtain hnRNP-PEG4-TCO and reactive tetrazine (Tz) on the ultrastable bifunctional chelator PCB-TE2A-alkyne to yield PCB-TE2A-Tz for the inverse electron demand Diels–Alder reaction. The 64Cu-radiolabeled antibody was administered and imaged at 1–18 h time points for conventional imaging. Alternatively, the unlabeled antibody conjugate was administered, and 48 h later radiolabeled 64Cu-PCB-TE2A-Tz was administered to the same mice for the pretargeting strategy and imaged at the same time intervals for direct comparison. The tumor was successfully visualized in both strategies, and comparatively, pretargeting showed superior results. The 64Cu-PCB-TE2A-Tz was successfully clicked at the tumor site with hnRNP-PEG4-TCO and the non-clicked were concurrently eliminated. This led to increase the tumor uptake with extremely high tumor-to-background ratio manifested by positron emission tomography (PET) imaging and biodistribution studies.
Collapse
Affiliation(s)
- Abhinav Bhise
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Hyun Park
- Division of Applied RI, Korea Institute of Radiological and Medical Science, Seoul 01812, Korea
| | - Woonghee Lee
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Swarbhanu Sarkar
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Yeong Su Ha
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Subramani Rajkumar
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Bora Nam
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Jeong Eun Lim
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Phuong Tu Huynh
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Kiwoong Lee
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Ji-Yoon Son
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
| | - Jung Young Kim
- Division of Applied RI, Korea Institute of Radiological and Medical Science, Seoul 01812, Korea
| | - Kyo Chul Lee
- Division of Applied RI, Korea Institute of Radiological and Medical Science, Seoul 01812, Korea
| | - Jeongsoo Yoo
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 41944, Korea
- Correspondence: ; Tel.: +82-53-420-4947
| |
Collapse
|
5
|
Mikulová MB, Mikuš P. Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics. Pharmaceuticals (Basel) 2021; 14:167. [PMID: 33669938 PMCID: PMC7924883 DOI: 10.3390/ph14020167] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 02/13/2021] [Accepted: 02/18/2021] [Indexed: 02/08/2023] Open
Abstract
Radiolabeled biomolecules targeted at tumor-specific enzymes, receptors, and transporters in cancer cells represent an intensively investigated and promising class of molecular tools for the cancer diagnosis and therapy. High specificity of such biomolecules is a prerequisite for the treatment with a lower burden to normal cells and for the effective and targeted imaging and diagnosis. Undoubtedly, early detection is a key factor in efficient dealing with many severe tumor types. This review provides an overview and critical evaluation of novel approaches in the designing of target-specific probes labeled with metal radionuclides for the diagnosis of most common death-causing cancers, published mainly within the last three years. Advances are discussed such traditional peptide radiolabeling approaches, and click and nanoparticle chemistry. The progress of radiolabeled peptide based ligands as potential radiopharmaceuticals is illustrated via novel structure and application studies, showing how the molecular modifications reflect their binding selectivity to significant onco-receptors, toxicity, and, by that, practical utilization. The most impressive outputs in categories of newly developed structures, as well as imaging and diagnosis approaches, and the most intensively studied oncological diseases in this context, are emphasized in order to show future perspectives of radiometal labeled amino acid-based compounds in nuclear medicine.
Collapse
Affiliation(s)
- Mária Bodnár Mikulová
- Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia;
| | - Peter Mikuš
- Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia;
- Toxicological and Antidoping Center (TAC), Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 832 32 Bratislava, Slovakia
| |
Collapse
|
6
|
Mewis RE, Archibald SJ. Side-bridged cyclam transition metal complexes bearing a phenolic ether or a phenolate pendent arm. Polyhedron 2019. [DOI: 10.1016/j.poly.2019.08.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
7
|
Carlos Dos Santos J, Beijer B, Bauder-Wüst U, Schäfer M, Leotta K, Eder M, Benešová M, Kleist C, Giesel F, Kratochwil C, Kopka K, Haberkorn U, Mier W. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. J Nucl Med 2019; 61:70-79. [PMID: 31541034 DOI: 10.2967/jnumed.119.229054] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 06/12/2019] [Indexed: 01/05/2023] Open
Abstract
Prostate-specific membrane antigen (PSMA)-binding tracers have been shown to be promising agents for the specific targeting of prostate tumors. On labeling with the short-lived isotopes 18F and 68Ga, excellent molecular imaging performance is achieved. This potential could be further exploited using long-lived isotopes. Because of the favorable half-life of 64Cu, tracers labeled with this PET nuclide could solve logistic problems. Moreover, this isotope provides a theranostic pair with the therapeutic copper isotope 67Cu. Hence, 9 novel tracers that combine dedicated copper chelators with the PSMA-specific urea-based binding motif were developed. Methods: The precursors were obtained by solid-phase synthesis. The purity and molecular weight of the PSMA ligands were confirmed by high-performance liquid chromatography and liquid chromatography-mass spectrometry. The compounds were labeled with 64Cu, with a radiolabeling yield of more than 99%. Competitive cell binding assays and internalization assays were performed with C4-2 cells, a subline of the PSMA-positive cell line LNCaP (human lymph node carcinoma of the prostate). In vitro serum stability, the stability of 64Cu-CA003 in blood, and the in vivo fate of neat 64Cu-chloride or 64Cu-CA003 were determined to prove whether the stability of the radiolabeled compounds is sufficient to ensure no significant loss of copper during the targeting process. For PET imaging and biodistribution studies, a C4-2 tumor-bearing mouse model was used. Results: The radiolabeled 64Cu-PSMA ligands showed high serum stability. All PSMA ligands showed high inhibition potencies, with equilibrium inhibition constants in the low nanomolar range. 64Cu-CA003 and 64Cu-CA005 showed high internalization ratios (34.6% ± 2.8 and 18.6% ± 4.4, respectively). Both the in vitro serum stability determination and the in vivo characterization of the main radiolabeled compounds confirmed that, except for 64Cu-PSMA-617, all compounds showed high serum stability within the observation period of 24 h. Small-animal PET imaging demonstrated high tumor uptake within 20 min. Organ distribution studies confirmed high specific uptake in the tumor, with 30.8 ± 12.6 percentage injected dose (%ID)/g at 1 h after injection. Rapid clearance from the kidneys was observed-a decrease from 67.0 ± 20.9 %ID/g at 1 h after injection to 7.5 ± 8.51 %ID/g at 24 h after injection (in the case of CA003). The performance of CA003, the compound with the best preclinical properties, was assessed in a first patient. In line with its preclinical data, PET imaging resulted in clear visualization of the cancer lesions, with high contrast. Conclusion: The 64Cu-labeled PSMA ligands are promising agents to target PSMA and visualize PSMA-positive tumor lesions as shown in preclinical evaluation by small-animal PET studies, organ distribution, and a patient application. Most importantly, the images obtained at 20 h enabled delineation of unclear lesions, showing that the compounds fulfill the prerequisite for dosimetry in the course of therapy planning with 67Cu. Thus, we suggest clinical use of copper-labeled CA003 for diagnostics and radiotherapy of prostate cancer.
Collapse
Affiliation(s)
| | - Barbro Beijer
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
| | - Ulrike Bauder-Wüst
- Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
| | - Martin Schäfer
- Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
| | - Karin Leotta
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
| | - Matthias Eder
- Division of Radiopharmaceutical Development, German Cancer Consortium Freiburg, Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany; and
| | - Martina Benešová
- Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
| | - Christian Kleist
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
| | - Frederik Giesel
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
| | - Clemens Kratochwil
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
| | - Klaus Kopka
- Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
| | - Uwe Haberkorn
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
| | - Walter Mier
- Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
| |
Collapse
|
8
|
Ahmedova A, Todorov B, Burdzhiev N, Goze C. Copper radiopharmaceuticals for theranostic applications. Eur J Med Chem 2018; 157:1406-1425. [DOI: 10.1016/j.ejmech.2018.08.051] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 08/15/2018] [Accepted: 08/18/2018] [Indexed: 12/12/2022]
|
9
|
Tolmachev V, Grönroos TJ, Yim CB, Garousi J, Yue Y, Grimm S, Rajander J, Perols A, Haaparanta-Solin M, Solin O, Ferdani R, Orlova A, Anderson CJ, Karlström AE. Molecular design of radiocopper-labelled Affibody molecules. Sci Rep 2018; 8:6542. [PMID: 29695813 PMCID: PMC5916907 DOI: 10.1038/s41598-018-24785-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 04/10/2018] [Indexed: 12/18/2022] Open
Abstract
The use of long-lived positron emitters 64Cu or 61Cu for labelling of Affibody molecules may improve breast cancer patients’ stratification for HER-targeted therapy. Previous animal studies have shown that the use of triaza chelators for 64Cu labelling of synthetic Affibody molecules is suboptimal. In this study, we tested a hypothesis that the use of cross-bridged chelator, CB-TE2A, in combination with Gly-Glu-Glu-Glu spacer for labelling of Affibody molecules with radiocopper would improve imaging contrast. CB-TE2A was coupled to the N-terminus of synthetic Affibody molecules extended either with a glycine (designation CB-TE2A-G-ZHER2:342) or Gly-Glu-Glu-Glu spacer (CB-TE2A-GEEE-ZHER2:342). Biodistribution and targeting properties of 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 were compared in tumor-bearing mice with the properties of 64Cu-NODAGA-ZHER2:S1, which had the best targeting properties in the previous study. 64Cu-CB-TE2A-GEEE-ZHER2:342 provided appreciably lower uptake in normal tissues and higher tumor-to-organ ratios than 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-NODAGA-ZHER2:S1. The most pronounced was a several-fold difference in the hepatic uptake. At the optimal time point, 6 h after injection, the tumor uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 was 16 ± 6%ID/g and tumor-to-blood ratio was 181 ± 52. In conclusion, a combination of the cross-bridged CB-TE2A chelator and Gly-Glu-Glu-Glu spacer is preferable for radiocopper labelling of Affibody molecules and, possibly, other scaffold proteins having high renal re-absorption.
Collapse
Affiliation(s)
- Vladimir Tolmachev
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
| | - Tove J Grönroos
- Turku PET Centre, University of Turku, Turku, Finland.,MediCity Research Laboratory, University of Turku, Turku, Finland.,Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
| | - Cheng-Bin Yim
- Turku PET Centre, University of Turku, Turku, Finland.,Turku PET Centre, Åbo Akademi University, Turku, Finland
| | - Javad Garousi
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Ying Yue
- Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Sebastian Grimm
- Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Johan Rajander
- Turku PET Centre, Åbo Akademi University, Turku, Finland
| | - Anna Perols
- Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Merja Haaparanta-Solin
- Turku PET Centre, University of Turku, Turku, Finland.,Department of Chemistry, University of Turku, Turku, Finland
| | - Olof Solin
- Turku PET Centre, University of Turku, Turku, Finland.,Turku PET Centre, Åbo Akademi University, Turku, Finland.,Department of Chemistry, University of Turku, Turku, Finland
| | | | - Anna Orlova
- Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
| | - Carolyn J Anderson
- Departments of Medicine, Radiology, Bioengineering and Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15203, USA
| | | |
Collapse
|
10
|
Skovgaard D, Persson M, Kjaer A. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. PET Clin 2017; 12:243-255. [PMID: 28267457 DOI: 10.1016/j.cpet.2016.12.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.
Collapse
Affiliation(s)
- Dorthe Skovgaard
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 9, 4011, Copenhagen, DK-2100, Denmark
| | - Morten Persson
- Curasight Aps, Ole Maaloesvej 3, Copenhagen, DK-2200, Denmark
| | - Andreas Kjaer
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 9, 4011, Copenhagen, DK-2100, Denmark.
| |
Collapse
|
11
|
Skovgaard D, Persson M, Kjaer A. PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives. Clin Transl Imaging 2016; 4:457-465. [PMID: 27933281 PMCID: PMC5118403 DOI: 10.1007/s40336-016-0197-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 06/25/2016] [Indexed: 11/30/2022]
Abstract
Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an important biomarker for aggressiveness in most common malignant diseases, including prostate cancer (PC). Accordingly, uPAR expression either assessed directly in malignant PC tissue or assessed directly in plasma (intact/cleaved forms)—provides independent additional clinical information to that contributed by PSA, Gleason score, and other relevant pathological and clinical parameters. In this respect, non-invasive molecular imaging by positron emission tomography (PET) offers a very attractive technology platform, which can provide the required quantitative information on the uPAR expression profile, without the need for invasive procedures and the risk of missing the target due to tumor heterogeneity. These observations support non-invasive PET imaging of uPAR in PC as a clinically relevant diagnostic and prognostic imaging method. In this review, we will focus on the recent development of uPAR PET and the relevance within prostate cancer imaging. Novel antibody and small-molecule radiotracers-targeting uPAR, including a series of uPAR-targeting PET ligands, based on the high affinity peptide ligand AE105, have been synthesized and tested in vitro and in vivo in preclinical murine xenograft models and, recently, in a first-ever clinical uPAR PET study in cancer patients, including patients with PC. In this phase I study, a high and specific uptake of the tracer 64Cu-DOTA-AE105 was found in both primary tumors and lymph node metastases. The results are encouraging and support large-scale clinical trials to determine the utility of uPAR PET in the management of patients with PC with the goal of improving outcome.
Collapse
Affiliation(s)
- Dorthe Skovgaard
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, National University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark
| | | | - Andreas Kjaer
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, National University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark
| |
Collapse
|
12
|
Halime Z, Frindel M, Camus N, Orain PY, Lacombe M, Bernardeau K, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R. New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative. Org Biomol Chem 2016; 13:11302-14. [PMID: 26419637 DOI: 10.1039/c5ob01618e] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Azamacrocyclic bifunctional chelating agents (BCAs) are essential for the development of radiopharmaceuticals in nuclear medicine and we wish to prove that their bioconjugation by a function present on a carbon atom of the macrocyclic skeleton is a solution of choice to maintain their in vivo inertness. Based on our very recent methodology using a bisaminal template and selective N-alkylation approach, a new synthesis of conjugable C-functionalised teta, te2a and cb-te2a has been developed. These chelators have indeed a growing interest in nuclear medicine for positron emission tomography (PET) and radioimmunotherapy (RIT) where they show in several cases better complexation properties than dota or dota-like macrocycles, especially with (64)Cu or (67)Cu radioisotopes. Chelators are bearing an isothiocyanate grafting function introduced by C-alkylation to avoid as much as possible a critical decrease of their chelating properties. The synthesis is very efficient and yields the targeted ligands, teta-Ph-NCS, te2a-Ph-NCS and cb-te2a-Ph-NCS without fastidious work-up and could be easily extended to other cyclam based-BCAs. The newly synthetised te2a-Ph-NCS has been conjugated to an anti mCD138 monoclonal antibody (mAb) to evaluate its in vivo behavior and potentiality as BCA and to explore a first attempt of PET-phenotypic imaging in multiple myeloma (MM). Mass spectrometry analysis of the immunoconjugate showed that up to 4 chelates were conjugated per 9E7.4 mAb. The radiolabeling yield and specific activity post-purification of the bioconjugate 9E7.4-CSN-Ph-te2a were 95 ± 2.8% and 188 ± 27 MBq mg(-1) respectively and the immunoreactivity of (64)Cu-9E7.4-CSN-Ph-te2a was 81 ± 7%. Animal experiments were carried out on 5T33-Luc(+) tumor bearing mice, either in subcutaneous or orthotopic. To achieve PET imaging, mice were injected with (64)Cu-9E7.4-CNS-Ph-te2a and acquisitions were conducted 2 and 20 h post-injection (PI). A millimetric bone uptake was localised in a sacroiliac of a MM orthotopic tumor. Nonspecific uptakes were observed at 2 h PI but, unlike for the tumor, a significant decrease was observed at 20 h PI which improves the contrast of the images.
Collapse
Affiliation(s)
- Zakaria Halime
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences et Techniques, 6 Avenue Victor le Gorgeu, C.S. 93837, 29238 Brest, France.
| | - Mathieu Frindel
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences et Techniques, 6 Avenue Victor le Gorgeu, C.S. 93837, 29238 Brest, France. and Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Unité INSERM 892 - CNRS 6299, 8 quai Moncousu, BP 70721 44007 Nantes Cedex, France
| | - Nathalie Camus
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences et Techniques, 6 Avenue Victor le Gorgeu, C.S. 93837, 29238 Brest, France.
| | - Pierre-Yves Orain
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences et Techniques, 6 Avenue Victor le Gorgeu, C.S. 93837, 29238 Brest, France.
| | - Marie Lacombe
- Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France
| | - Karine Bernardeau
- Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Unité INSERM 892 - CNRS 6299, 8 quai Moncousu, BP 70721 44007 Nantes Cedex, France
| | - Michel Chérel
- Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France
| | | | | | - Raphaël Tripier
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences et Techniques, 6 Avenue Victor le Gorgeu, C.S. 93837, 29238 Brest, France.
| |
Collapse
|
13
|
Jurek P, Reibenspies JH, Kiefer GE. CB-TE2A(+)·Cl(-)·3H2O: a short intermolecular hydrogen bond between zwitterionic bicyclo[6.6.2]tetraamine macrocycles. ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY 2016; 72:139-42. [PMID: 26846499 DOI: 10.1107/s2053229616000358] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2015] [Accepted: 01/07/2016] [Indexed: 11/10/2022]
Abstract
1,4,8,11-Tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A) is of much interest in nuclear medicine for its ability to form copper complexes that are kinetically inert, which is beneficial in vivo to minimize the loss of radioactive copper. The structural chemistry of the hydrated HCl salt of CB-TE2A, namely 11-carboxymethyl-1,8-tetraaza-4,11-diazoniabicyclo[6.6.2]hexadecane-4-acetate chloride trihydrate, C16H31N4O4(+)·Cl(-)·3H2O, is described. The compound crystallized as a positively charged zwitterion with a chloride counter-ion. Two of the amine groups in the macrocyclic ring are protonated. Formally, a single negative charge is shared between two of the carboxylic acid groups, while one chloride ion balances the charge. Two intramolecular hydrogen bonds are observed between adjacent pairs of N atoms of the macrocycle. Two intramolecular hydrogen bonds are also observed between the protonated amine groups and the pendant carboxylate groups. A short intermolecular hydrogen bond is observed between two partially negatively charged O atoms on adjacent macrocycles. The result is a one-dimensional polymeric zigzag chain that propagates parallel to the crystallographic a direction. A second intermolecular interaction is a hydrogen-bonding network in the crystallographic b direction. The carbonyl group of one macrocycle is connected through the three water molecules of hydration to the carbonyl group of another macrocycle.
Collapse
Affiliation(s)
- Paul Jurek
- Macrocyclics, Inc., 1309 Record Crossing, Dallas TX 75235, USA
| | | | - Garry E Kiefer
- Macrocyclics, Inc., 1309 Record Crossing, Dallas TX 75235, USA
| |
Collapse
|
14
|
Ramogida CF, Boros E, Patrick BO, Zeisler SK, Kumlin J, Adam MJ, Schaffer P, Orvig C. Evaluation of H2CHXdedpa, H2dedpa- and H2CHXdedpa-N,N′-propyl-2-NI ligands for 64Cu(ii) radiopharmaceuticals. Dalton Trans 2016; 45:13082-90. [DOI: 10.1039/c6dt00932h] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Hexadentate acyclic chelate H2CHXdedpa and related N,N′-alkylated ligands are radiolabeled with radioactive 64Cu(ii) under mild conditions forming kinetically inert complexes.
Collapse
Affiliation(s)
- Caterina F. Ramogida
- Medicinal Inorganic Chemistry Group
- Department of Chemistry
- University of British Columbia
- Vancouver
- Canada
| | - Eszter Boros
- Medicinal Inorganic Chemistry Group
- Department of Chemistry
- University of British Columbia
- Vancouver
- Canada
| | - Brian O. Patrick
- Medicinal Inorganic Chemistry Group
- Department of Chemistry
- University of British Columbia
- Vancouver
- Canada
| | | | | | | | | | - Chris Orvig
- Medicinal Inorganic Chemistry Group
- Department of Chemistry
- University of British Columbia
- Vancouver
- Canada
| |
Collapse
|
15
|
Sok N, Baglin I, Rousselin Y, Boschetti F, Bernhard C, Goze C, Denat F. Reinforced cyclam derivatives functionalized on the bridging unit. NEW J CHEM 2016. [DOI: 10.1039/c5nj03488d] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The introduction of one or two nitriles on the bridge of reinforced cyclams paves the way for the synthesis of new bifunctional chelating agents. X-ray structures of the chelators and of two copper complexes are reported.
Collapse
Affiliation(s)
- Nicolas Sok
- AgroSupDijon
- UMR PAM
- PCAV team
- 21000 Dijon
- France
| | - Isabelle Baglin
- ICMUB
- UMR CNRS 6302
- Université de Bourgogne Franche-Comté
- 21000 Dijon
- France
| | - Yoann Rousselin
- ICMUB
- UMR CNRS 6302
- Université de Bourgogne Franche-Comté
- 21000 Dijon
- France
| | | | - Claire Bernhard
- ICMUB
- UMR CNRS 6302
- Université de Bourgogne Franche-Comté
- 21000 Dijon
- France
| | - Christine Goze
- ICMUB
- UMR CNRS 6302
- Université de Bourgogne Franche-Comté
- 21000 Dijon
- France
| | - Franck Denat
- ICMUB
- UMR CNRS 6302
- Université de Bourgogne Franche-Comté
- 21000 Dijon
- France
| |
Collapse
|
16
|
Burke BP, Seemann J, Archibald SJ. Advanced Chelator Design for Metal Complexes in Imaging Applications. ADVANCES IN INORGANIC CHEMISTRY 2016. [DOI: 10.1016/bs.adioch.2015.11.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
17
|
Paterson BM, Donnelly PS. Macrocyclic Bifunctional Chelators and Conjugation Strategies for Copper-64 Radiopharmaceuticals. ADVANCES IN INORGANIC CHEMISTRY 2016. [DOI: 10.1016/bs.adioch.2015.09.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
18
|
Litau S, Seibold U, Vall-Sagarra A, Fricker G, Wängler B, Wängler C. Comparative Assessment of Complex Stabilities of Radiocopper Chelating Agents by a Combination of Complex Challenge and in vivo Experiments. ChemMedChem 2015; 10:1200-8. [PMID: 26011290 DOI: 10.1002/cmdc.201500132] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Indexed: 12/12/2022]
Abstract
For (64) Cu radiolabeling of biomolecules to be used as in vivo positron emission tomography (PET) imaging agents, various chelators are commonly applied. It has not yet been determined which of the most potent chelators--NODA-GA ((1,4,7-triazacyclononane-4,7-diyl)diacetic acid-1-glutaric acid), CB-TE2A (2,2'-(1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diyl)diacetic acid), or CB-TE1A-GA (1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diyl-8-acetic acid-1-glutaric acid)--forms the most stable complexes resulting in PET images of highest quality. We determined the (64) Cu complex stabilities for these three chelators by a combination of complex challenge and an in vivo approach. For this purpose, bioconjugates of the chelating agents with the gastrin-releasing peptide receptor (GRPR)-affine peptide PESIN and an integrin αv β3 -affine c(RGDfC) tetramer were synthesized and radiolabeled with (64) Cu in excellent yields and specific activities. The (64) Cu-labeled biomolecules were evaluated for their complex stabilities in vitro by conducting a challenge experiment with the respective other chelators as challengers. The in vivo stabilities of the complexes were also determined, showing the highest stability for the (64) Cu-CB-TE1A-GA complex in both experimental setups. Therefore, CB-TE1A-GA is the most appropriate chelating agent for *Cu-labeled radiotracers and in vivo imaging applications.
Collapse
Affiliation(s)
- Shanna Litau
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany).,Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany)
| | - Uwe Seibold
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany).,Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany)
| | - Alicia Vall-Sagarra
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany)
| | - Gert Fricker
- Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Im Neuenheimer Feld 329, 69120 Heidelberg (Germany)
| | - Björn Wängler
- Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany)
| | - Carmen Wängler
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim (Germany).
| |
Collapse
|
19
|
Camus N, Halime Z, le Bris N, Bernard H, Beyler M, Platas-Iglesias C, Tripier R. A [two-step/one week] synthesis of C-functionalized homocyclens and cyclams. Application to the preparation of conjugable BCAs without chelating properties alteration. RSC Adv 2015. [DOI: 10.1039/c5ra17133d] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
An efficient synthesis ofC-functionalized azamacrocycles is presented together with a coordination study showing the week influence of the added appended group.
Collapse
Affiliation(s)
- Nathalie Camus
- Université de Brest
- UMR-CNRS 6521/SFR148 ScInBioS UFR Sciences et Techniques
- 29238 Brest
- France
| | - Zakaria Halime
- Université de Brest
- UMR-CNRS 6521/SFR148 ScInBioS UFR Sciences et Techniques
- 29238 Brest
- France
| | - Nathalie le Bris
- Université de Brest
- UMR-CNRS 6521/SFR148 ScInBioS UFR Sciences et Techniques
- 29238 Brest
- France
| | - Hélène Bernard
- Université de Brest
- UMR-CNRS 6521/SFR148 ScInBioS UFR Sciences et Techniques
- 29238 Brest
- France
| | - Maryline Beyler
- Université de Brest
- UMR-CNRS 6521/SFR148 ScInBioS UFR Sciences et Techniques
- 29238 Brest
- France
| | - Carlos Platas-Iglesias
- Grupo QUICOOR
- Centro de Investigaciones Científicas Avanzadas (CICA) and Departamento de Química Fundamental
- Universidade da Coruña
- Campus da Zapateira
- 15008 A Coruña
| | - Raphaël Tripier
- Université de Brest
- UMR-CNRS 6521/SFR148 ScInBioS UFR Sciences et Techniques
- 29238 Brest
- France
| |
Collapse
|
20
|
Pandya DN, Bhatt N, An GI, Ha YS, Soni N, Lee H, Lee YJ, Kim JY, Lee W, Ahn H, Yoo J. Propylene Cross-Bridged Macrocyclic Bifunctional Chelator: A New Design for Facile Bioconjugation and Robust 64Cu Complex Stability. J Med Chem 2014; 57:7234-43. [DOI: 10.1021/jm500348z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Darpan N. Pandya
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| | - Nikunj Bhatt
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| | - Gwang Il An
- Molecular
Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
| | - Yeong Su Ha
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| | - Nisarg Soni
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| | - Hochun Lee
- Department of Energy Systems Engineering, Daegu Gyeongbuk Institute of Science & Technology, Daegu 711-873, South Korea
| | - Yong Jin Lee
- Molecular
Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
| | - Jung Young Kim
- Molecular
Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
| | - Woonghee Lee
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| | - Heesu Ahn
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| | - Jeongsoo Yoo
- Department
of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu 700-422, South Korea
| |
Collapse
|
21
|
Lima LMP, Halime Z, Marion R, Camus N, Delgado R, Platas-Iglesias C, Tripier R. Monopicolinate Cross-Bridged Cyclam Combining Very Fast Complexation with Very High Stability and Inertness of Its Copper(II) Complex. Inorg Chem 2014; 53:5269-79. [DOI: 10.1021/ic500491c] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Luís M. P. Lima
- Instituto
de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
| | - Zakaria Halime
- Université
de Bretagne Occidentale, UMR-CNRS 6521, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238 Brest Cedex 3, France
| | - Ronan Marion
- Université
de Bretagne Occidentale, UMR-CNRS 6521, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238 Brest Cedex 3, France
| | - Nathalie Camus
- Université
de Bretagne Occidentale, UMR-CNRS 6521, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238 Brest Cedex 3, France
| | - Rita Delgado
- Instituto
de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
| | - Carlos Platas-Iglesias
- Departamento de Química Fundamental, Universidade da Coruña, Campus da Zapateira, Rúa da Fraga 10, 15008 A Coruña, Spain
| | - Raphaël Tripier
- Université
de Bretagne Occidentale, UMR-CNRS 6521, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238 Brest Cedex 3, France
| |
Collapse
|
22
|
Jensen AI, Binderup T, Kumar EK P, Kjær A, Rasmussen PH, Andresen TL. Positron Emission Tomography Based Analysis of Long-Circulating Cross-Linked Triblock Polymeric Micelles in a U87MG Mouse Xenograft Model and Comparison of DOTA and CB-TE2A as Chelators of Copper-64. Biomacromolecules 2014; 15:1625-33. [DOI: 10.1021/bm401871w] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Andreas I. Jensen
- The
Hevesy Laboratory, DTU Nutech, Technical University of Denmark, Roskilde, Denmark
- Department
of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics,
DTU Nanotech, Technical University of Denmark, Building 423, 2800 Lyngby, Denmark
| | - Tina Binderup
- Cluster
for Molecular Imaging and Department of Clinical Physiology, Nuclear
Medicine, and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Pramod Kumar EK
- Department
of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics,
DTU Nanotech, Technical University of Denmark, Building 423, 2800 Lyngby, Denmark
| | - Andreas Kjær
- Cluster
for Molecular Imaging and Department of Clinical Physiology, Nuclear
Medicine, and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Palle H. Rasmussen
- The
Hevesy Laboratory, DTU Nutech, Technical University of Denmark, Roskilde, Denmark
| | - Thomas L. Andresen
- Department
of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics,
DTU Nanotech, Technical University of Denmark, Building 423, 2800 Lyngby, Denmark
| |
Collapse
|
23
|
Cai Z, Anderson CJ. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J Labelled Comp Radiopharm 2014; 57:224-30. [PMID: 24347474 PMCID: PMC4277819 DOI: 10.1002/jlcr.3165] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Accepted: 10/29/2013] [Indexed: 12/27/2022]
Abstract
The development of chelating agents for copper radionuclides in positron emission tomography radiopharmaceuticals has been a highly active and important area of study in recent years. The rapid evolution of chelators has resulted in highly specific copper chelators that can be readily conjugated to biomolecules and efficiently radiolabeled to form stable complexes in vivo. Chelators are not only designed for conjugation to monovalent biomolecules but also for incorporation into multivalent targeting ligands such as theranostic nanoparticles. These advancements have strengthened the role of copper radionuclides in the fields of nuclear medicine and molecular imaging. This review emphasizes developments of new copper chelators that have most greatly advanced the field of copper-based radiopharmaceuticals over the past 5 years.
Collapse
Affiliation(s)
- Zhengxin Cai
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA 15219, USA
| | - Carolyn J. Anderson
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA 15219, USA
| |
Collapse
|
24
|
Camus N, Halime Z, Le Bris N, Bernard H, Platas-Iglesias C, Tripier R. Full Control of the Regiospecific N-Functionalization of C-Functionalized Cyclam Bisaminal Derivatives and Application to the Synthesis of their TETA, TE2A, and CB-TE2A Analogues. J Org Chem 2014; 79:1885-99. [DOI: 10.1021/jo4028566] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Nathalie Camus
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences
et Techniques, 6 Avenue Victor le Gorgeu,
C.S. 93837, 29238 Brest, France
| | - Zakaria Halime
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences
et Techniques, 6 Avenue Victor le Gorgeu,
C.S. 93837, 29238 Brest, France
| | - Nathalie Le Bris
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences
et Techniques, 6 Avenue Victor le Gorgeu,
C.S. 93837, 29238 Brest, France
| | - Hélène Bernard
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences
et Techniques, 6 Avenue Victor le Gorgeu,
C.S. 93837, 29238 Brest, France
| | - Carlos Platas-Iglesias
- Departamento
de Química Fundamental, Universidade da Coruña, Campus
da Zapateira, Rúa da Fraga 10, 15008 A Coruña, Spain
| | - Raphaël Tripier
- Université de Brest, UMR-CNRS 6521/SFR148 ScInBioS, UFR Sciences
et Techniques, 6 Avenue Victor le Gorgeu,
C.S. 93837, 29238 Brest, France
| |
Collapse
|
25
|
Ramogida CF, Orvig C. Tumour targeting with radiometals for diagnosis and therapy. Chem Commun (Camb) 2013; 49:4720-39. [PMID: 23599005 DOI: 10.1039/c3cc41554f] [Citation(s) in RCA: 177] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Use of radiometals in nuclear oncology is a rapidly growing field and encompasses a broad spectrum of radiotracers for imaging via PET (positron emission tomography) or SPECT (single-photon emission computed tomography) and therapy via α, β(-), or Auger electron emission. This feature article opens with a brief introduction to the imaging and therapy modalities exploited in nuclear medicine, followed by a discussion of the multi-component strategy used in radiopharmaceutical development, known as the bifunctional chelate (BFC) method. The modular assembly is dissected into its individual components and each is discussed separately. The concepts and knowledge unique to metal-based designs are outlined, giving insight into how these radiopharmaceuticals are evaluated for use in vivo. Imaging nuclides (64)Cu, (68)Ga, (86)Y, (89)Zr, and (111)In, and therapeutic nuclides (90)Y, (177)Lu, (225)Ac, (213)Bi, (188)Re, and (212)Pb will be the focus herein. Finally, key examples have been extracted from the literature to give the reader a sense of breadth of the field.
Collapse
Affiliation(s)
- Caterina F Ramogida
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1
| | | |
Collapse
|
26
|
Abstract
Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly harnessed, these have valuable emission properties that can be used for diagnostic imaging techniques, such as single photon emission computed tomography (SPECT, e.g.(67)Ga, (99m)Tc, (111)In, (177)Lu) and positron emission tomography (PET, e.g.(68)Ga, (64)Cu, (44)Sc, (86)Y, (89)Zr), as well as therapeutic applications (e.g.(47)Sc, (114m)In, (177)Lu, (90)Y, (212/213)Bi, (212)Pb, (225)Ac, (186/188)Re). A fundamental critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. This article is a guide for selecting the optimal match between chelator and radiometal for use in these systems. The article briefly introduces a selection of relevant and high impact radiometals, and their potential utility to the fields of radiochemistry, nuclear medicine, and molecular imaging. A description of radiometal-based radiopharmaceuticals is provided, and several key design considerations are discussed. The experimental methods by which chelators are assessed for their suitability with a variety of radiometal ions is explained, and a large selection of the most common and most promising chelators are evaluated and discussed for their potential use with a variety of radiometals. Comprehensive tables have been assembled to provide a convenient and accessible overview of the field of radiometal chelating agents.
Collapse
Affiliation(s)
- Eric W Price
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, CanadaV6T 1Z1.
| | | |
Collapse
|
27
|
Dissociation kinetics study of copper(II) complexes of DO3A, DOTA and its monosubstituted derivatives. Polyhedron 2013. [DOI: 10.1016/j.poly.2013.05.042] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
28
|
Persson M, Hosseini M, Madsen J, Jørgensen TJD, Jensen KJ, Kjaer A, Ploug M. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies. Theranostics 2013; 3:618-32. [PMID: 24052804 PMCID: PMC3776215 DOI: 10.7150/thno.6810] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 07/21/2013] [Indexed: 12/17/2022] Open
Abstract
The correlation between uPAR expression, cancer cell invasion and metastases is now well-established and has prompted the development of a number of uPAR PET imaging agents, which could potentially identify cancer patients with invasive and metastatic lesions. In the present study, we synthesized and characterized two new cross-bridged 64Cu-labeled peptide conjugates for PET imaging of uPAR and performed a head-to-head comparison with the corresponding and more conventionally used DOTA conjugate. Based on in-source laser-induced reduction of chelated Cu(II) to Cu(I), we now demonstrate the following ranking with respect to the chemical inertness of their complexed Cu ions: DOTA-AE105 << CB-TE2A-AE105 < CB-TE2A-PA-AE105, which is correlated to their corresponding demetallation rate. No penalty in the uPAR receptor binding affinity of the targeting peptide was encountered by conjugation to either of the macrobicyclic chelators (IC50 ~ 5-10 nM) and high yields and radiochemical purities (>95%) were achieved in all cases by incubation at 95ºC. In vivo, they display identical tumor uptake after 1h, but differ significantly after 22 hrs, where the DOTA-AE105 uptake remains surprisingly high. Importantly, the more stable of the new uPAR PET tracers, 64Cu-CB-TE2A-PA-AE105, exhibits a significantly reduced liver uptake compared to 64Cu-DOTA-AE105 as well as 64Cu-CB-TE2A-AE105, (p<0.0001), emphasizing that our new in vitro stability measurements by mass spectrometry predicts in vivo stability in mice. Specificity of the best performing ligand, 64Cu-CB-TE2A-PA-AE105 was finally confirmed in vivo using a non-binding 64Cu-labeled peptide as control (64Cu-CB-TE2A-PA-AE105mut). This control PET-tracer revealed significantly reduced tumor uptake (p<0.0001), but identical hepatic uptake compared to its active counterpart (64Cu-CB-TE2A-PA-AE105) after 1h. In conclusion, our new approach using in-source laser-induced reduction of Cu(II)-chelated PET-ligands provides useful information, which are predictive for the tracer stability in vivo in mice. Furthermore, the increased stability of our new macrobicyclic 64Cu-CB-TE2A-PA-AE105 PET ligand is paralleled by an excellent imaging contrast during non-invasive PET scanning of uPAR expression in preclinical mouse cancer models. The translational promises displayed by this PET-tracer for future clinical cancer patient management remains, however, to be investigated.
Collapse
|
29
|
Hueting R, Tavaré R, Dilworth JR, Mullen GE. Copper-64 radiolabelling of the C2A domain of synaptotagmin I using a functionalised bis(thiosemicarbazone): A pre- and post-labelling comparison. J Inorg Biochem 2013; 128:108-11. [PMID: 23954480 DOI: 10.1016/j.jinorgbio.2013.07.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Revised: 07/08/2013] [Accepted: 07/08/2013] [Indexed: 12/19/2022]
Abstract
Dysregulation of apoptosis and necrosis is central to many diseases and non-invasive imaging of cell death is an important clinical objective to stage disease or to monitor treatment progress. The C2A domain of rat synaptotagmin I binds to phosphatidylserine (PS) exposed during cell death and modification to its lysine residues has been shown to disrupt PS binding. Site-specifically labelled (99m)Tc(CO)3-C2AcH and (68)Ga-C2Ac have previously been investigated for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, respectively. We wished to design a (64)Cu-labelled counterpart due to the longer half-life of (64)Cu. Since the calcium binding sites in C2A may interfere with copper binding we sought a high affinity, fast labelling chelator. We synthesised a maleimide functionalised bis(thiosemicarbazone), H2ATSE/AMal, for the site-specific copper-64 radiolabelling of thiol-functionalised C2Ac. When radiolabelling was performed by incubation of the ligand-protein conjugate (post-labelling approach), analysis of the resultant (64)CuATSE/AMal-C2Ac revealed that the C2Ac was able to compete for radiocopper with the chelator. In contrast, the pre-labelled (64)CuATSE/AMal-C2Ac conjugate revealed good stability in serum and maintained target affinity in a red blood cell binding assay. The results suggest that due to the intrinsic copper binding properties of the protein, a pre-labelling approach is preferred for the C2Ac domain of synaptotagmin I when copper is the desired radioisotope.
Collapse
Affiliation(s)
- Rebekka Hueting
- Chemistry Research Laboratory, University of Oxford, Oxford, United Kingdom; Division of Imaging Sciences & Biomedical Engineering, King's College London, St. Thomas' Hospital, London, United Kingdom
| | | | | | | |
Collapse
|
30
|
Roger M, Lima LMP, Frindel M, Platas-Iglesias C, Gestin JF, Delgado R, Patinec V, Tripier R. Monopicolinate-dipicolyl derivative of triazacyclononane for stable complexation of Cu2+ and 64Cu2+. Inorg Chem 2013; 52:5246-59. [PMID: 23581283 DOI: 10.1021/ic400174r] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
The synthesis and characterization of Hno1pa2py, a new tacn-based ligand, is reported. The complexation process with Cu(2+) was proved to be very fast even in acidic medium. Potentiometric titrations allowed us to establish that Hno1pa2py exhibits an overall low basicity as well as a high selectivity for Cu(2+) over Zn(2+) cations. The copper(II) complex was synthesized and characterized using UV-vis and EPR spectroscopies and density functional theory (DFT) calculations. The studies clearly showed that the [Cu(no1pa2py)](+) complex is present in solution as a mixture of two isomers in which the ligand is coordinated to the metal center using a N5O donor set with the metal center in a distorted octahedral geometry. The very high kinetic inertness of the [Cu(no1pa2py)](+) complex was demonstrated by using acid-assisted dissociation assays as well as cyclic voltammetry. Preliminary investigations of (64)Cu complexation were performed to validate the potential use of such chelating agent for further application in nuclear medicine. The X-ray crystal structures of copper(II) complexes of L1, the ester derivative of Hno1pa2py, have been determined.
Collapse
Affiliation(s)
- Melissa Roger
- Université de Bretagne Occidentale, UMR-CNRS 6521, UFR des Sciences et Techniques, 6 avenue Victor le Gorgeu, C.S. 93837, 29238 Brest Cedex 3, France
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Esteves CV, Lamosa P, Delgado R, Costa J, Désogère P, Rousselin Y, Goze C, Denat F. Remarkable Inertness of Copper(II) Chelates of Cyclen-Based Macrobicycles with Two trans-N-Acetate Arms. Inorg Chem 2013; 52:5138-53. [DOI: 10.1021/ic400015v] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Catarina V. Esteves
- Instituto
de Tecnologia Química e Biológica, Universidade Nova
de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
| | - Pedro Lamosa
- Instituto
de Tecnologia Química e Biológica, Universidade Nova
de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
| | - Rita Delgado
- Instituto
de Tecnologia Química e Biológica, Universidade Nova
de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
| | - Judite Costa
- iMed.UL, Faculdade de Farmácia,
Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Pauline Désogère
- Institut de Chimie Moléculaire
de l’Université de Bourgogne, UMR CNRS 6302, Université
de Bourgogne, 9, Av. Alain Savary, 21078 Dijon, France
| | - Yoann Rousselin
- Institut de Chimie Moléculaire
de l’Université de Bourgogne, UMR CNRS 6302, Université
de Bourgogne, 9, Av. Alain Savary, 21078 Dijon, France
| | - Christine Goze
- Institut de Chimie Moléculaire
de l’Université de Bourgogne, UMR CNRS 6302, Université
de Bourgogne, 9, Av. Alain Savary, 21078 Dijon, France
| | - Franck Denat
- Institut de Chimie Moléculaire
de l’Université de Bourgogne, UMR CNRS 6302, Université
de Bourgogne, 9, Av. Alain Savary, 21078 Dijon, France
| |
Collapse
|
32
|
Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules 2013; 18:3379-409. [PMID: 23493103 PMCID: PMC6269889 DOI: 10.3390/molecules18033379] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Revised: 02/25/2013] [Accepted: 03/07/2013] [Indexed: 12/20/2022] Open
Abstract
Despite the advances in molecular biology and biochemistry, the prognosis of patients suffering from tumor diseases remains poor. The limited therapeutic success can be explained by the insufficient performance of the common chemotherapeutic drugs that lack the ability to specifically target tumor tissues. Recently peptide radiopharmaceuticals have been developed that enable the concurrent imaging and therapy of tumors expressing a specific target. Here, with a special emphasis on the synthesis of the building blocks required for the complexation of metallic radioisotopes, the requirements to the design and synthesis of radiolabeled peptides for clinical applications are described.
Collapse
Affiliation(s)
| | | | - Walter Mier
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +49-6221-56-7720; Fax: +49-6221-65-33629
| |
Collapse
|
33
|
Désogère P, Bernhard C, Goze C, Penouilh MJ, Rousselin Y, Denat F. Selectively Functionalized Constrained Polyazamacrocycles: Building Blocks for Multifunctional Chelating Agents. European J Org Chem 2013. [DOI: 10.1002/ejoc.201201337] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
34
|
Martin ME, O'Dorisio MS, Leverich WM, Kloepping KC, Schultz MK, Schultz MK. "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system. Recent Results Cancer Res 2013; 194:149-75. [PMID: 22918759 PMCID: PMC3799893 DOI: 10.1007/978-3-642-27994-2_9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Cyclization techniques are used often to impart higher in vivo stability and binding affinity to peptide targeting vectors for molecular imaging and therapy. The two most often used techniques to impart these qualities are lactam bridge construction and disulfide bond formation. While these techniques have been demonstrated to be effective, orthogonal protection/deprotection steps can limit achievable product yields. In the work described in this chapter, new α-melanocyte stimulating hormone (α-MSH) peptide analogs were synthesized and cyclized by copper-catalyzed terminal azide-alkyne cycloaddition "click" chemistry techniques. The α-MSH peptide and its cognate receptor (melanocortin receptor subtype 1, MC1R) represent a well-characterized model system to examine the effect of the triazole linkage for peptide cyclization on receptor binding in vitro and in vivo. Four new DOTA-conjugated α-MSH analogs were cyclized and evaluated by in vitro competitive binding assays, serum stability testing, and in vivo imaging by positron emission tomography (PET) of tumor-bearing mice. These new DOTA-conjugated click-cyclized analogs exhibited selective high binding affinity (<2 nM) for MC1R on melanoma cells in vitro, high stability in human serum, and produced high-contrast PET/CT images of tumor xenografts. (68)Ga-labeled DOTA bioconjugates displayed rapid pharmacokinetics with receptor-mediated tumor accumulation of up to 16 ± 5% ID/g. The results indicate that the triazole ring is an effective bioisosteric replacement for the standard lactam bridge assemblage for peptide cyclization. Radiolabeling results confirm that Cu catalyst is sufficiently removed prior to DOTA chelator addition to enable insertion of radio metals or stable metals for molecular imaging and therapy. Thus, these click-chemistry-cyclized variants show promise as agents for melanocortin receptor-targeted imaging and radionuclide therapy.
Collapse
Affiliation(s)
- Molly E. Martin
- Department of Pediatric Hematology/Oncology, Carver College of Medicine, The University of Iowa
| | - M. Sue O'Dorisio
- Department of Pediatric Hematology/Oncology, Carver College of Medicine, The University of Iowa,Corresponding Author: Michael K. Schultz PhD, Departments of Radiology and Radiation Oncology (Free Radical Radiation Biology Program), Carver College of Medicine, The University of Iowa, ML B180, 500 Newton Road, Iowa City, IA 52242. Tel: +1 (319) 356-3380; Fax: +1 (319) 335-8668;
| | - Whitney M. Leverich
- Department of Pediatric Hematology/Oncology, Carver College of Medicine, The University of Iowa
| | - Kyle C. Kloepping
- Department of Radiology, Carver College of Medicine, The University of Iowa,Department of Radiation Oncology (Free Radical Radiation Biology Program), Carver College of Medicine, The University of Iowa
| | - Michael K. Schultz
- Department of Radiology, Carver College of Medicine, The University of Iowa,Department of Radiation Oncology (Free Radical Radiation Biology Program), Carver College of Medicine, The University of Iowa,Corresponding Author: Michael K. Schultz PhD, Departments of Radiology and Radiation Oncology (Free Radical Radiation Biology Program), Carver College of Medicine, The University of Iowa, ML B180, 500 Newton Road, Iowa City, IA 52242. Tel: +1 (319) 356-3380; Fax: +1 (319) 335-8668;
| | | |
Collapse
|
35
|
Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv 2012; 2:769-91. [PMID: 22822508 DOI: 10.4155/tde.11.41] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The therapeutic rationale of antibody conjugates is the selective delivery of a cytotoxin to tumor cells via binding and internalization of the monoclonal antibodies to a specific cell-surface antigen, thereby enhancing the therapeutic index of the cytotoxin. The key structural and functional components of an antibody conjugate are the antibody, the linker and the cytotoxin (chemical or radionuclide) with each component being critical for the successful development of the conjugate. Considerable efforts have been made in understanding the pharmacokinetics, pharmacodynamics, tissue distribution, metabolism and pharmacologic effects of these complex macromolecular entities. The purpose of this article is to discuss the properties and various structural components of antibody conjugates that influence their clinical pharmacology.
Collapse
|
36
|
Carroll V, Demoin DW, Hoffman TJ, Jurisson SS. Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. RADIOCHIM ACTA 2012; 100:653-667. [PMID: 25382874 PMCID: PMC4221859 DOI: 10.1524/ract.2012.1964] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Radiometals play an important role in diagnostic and therapeutic radiopharmaceuticals. This field of radiochemistry is multidisciplinary, involving radiometal production, separation of the radiometal from its target, chelate design for complexing the radiometal in a biologically stable environment, specific targeting of the radiometal to its in vivo site, and nuclear imaging and/or radiotherapy applications of the resultant radiopharmaceutical. The critical importance of inorganic chemistry in the design and application of radiometal-containing imaging and therapy agents is described from a historical perspective to future directions.
Collapse
Affiliation(s)
| | | | - Timothy J Hoffman
- Chemistry, University of Missouri, Columbia, MO 65211, USA
- Internal Medicine, University of Missouri, Columbia, MO 65211, USA
- Harry S Truman Memorial Veterans Hospital, Columbia, MO 65211, USA
| | | |
Collapse
|
37
|
Bartholomä MD. Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in Positron Emission Tomography. Inorganica Chim Acta 2012. [DOI: 10.1016/j.ica.2012.01.061] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Pandya DN, Dale AV, Kim JY, Lee H, Ha YS, An GI, Yoo J. New macrobicyclic chelator for the development of ultrastable 64Cu-radiolabeled bioconjugate. Bioconjug Chem 2012; 23:330-5. [PMID: 22329542 DOI: 10.1021/bc200539t] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Ethylene cross-bridged cyclam with two acetate pendant arms, ECB-TE2A, is known to form the most kinetically stable (64)Cu complexes. However, its usefulness as a bifunctional chelator is limited because of its harsh radiolabeling conditions. Herein, we report new cross-bridged cyclam chelator for the development of ultrastable (64)Cu-radiolabeled bioconjugates. Propylene cross-bridged TE2A (PCB-TE2A) was successfully synthesized in an efficient way. The Cu(II) complex of PCB-TE2A exhibited much higher kinetic stability than ECB-TE2A in acid decomplexation studies, and also showed high resistance to reduction-mediated demetalation. Furthermore, the quantitative radiolabeling of PCB-TE2A with (64)Cu was achieved under milder conditions compared to ECB-TE2A. Biodistribution studies strongly indicate that the (64)Cu complexes of PCB-TE2A cleared out rapidly from the body with minimum decomplexation.
Collapse
Affiliation(s)
- Darpan N Pandya
- Department of Molecular Medicine, Kyungpook National University, Daegu 700-422, South Korea
| | | | | | | | | | | | | |
Collapse
|
39
|
Ferdani R, Stigers DJ, Fiamengo AL, Wei L, Li BTY, Golen JA, Rheingold AL, Weisman GR, Wong EH, Anderson CJ. Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms. Dalton Trans 2012; 41:1938-50. [PMID: 22170043 PMCID: PMC3462348 DOI: 10.1039/c1dt11743b] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A new class of cross-bridged cyclam-based macrocycles featuring phosphonate pendant groups has been developed. 1,4,8,11-tetraazacyclotetradecane-1,8-di(methanephosphonic acid) (CB-TE2P, 1) and 1,4,8,11-tetraazacyclotetradecane-1-(methanephosphonic acid)-8-(methanecarboxylic acid) (CB-TE1A1P, 2) have been synthesized and have been shown to readily form neutral copper(II) complexes at room temperature as the corresponding dianions. Both complexes showed high kinetic inertness to demetallation and crystal structures confirmed complete encapsulation of copper(II) ion within each macrocycle's cleft-like structure. Unprecedented for cross-bridged cyclam derivatives, both CB-TE2P (1) and CB-TE1A1P (2) can be radiolabeled with (64)Cu at room temperature in less than 1 h with specific activities >1 mCi μg(-1). The in vivo behavior of both (64)Cu-CB-TE2P and (64)Cu-CB-TE1A1P were investigated through biodistribution studies using healthy male Lewis rats. Both new compounds showed rapid clearance with similar or lower accumulation in non-target organs/tissues when compared to other copper chelators including CB-TE2A, NOTA and Diamsar.
Collapse
Affiliation(s)
- Riccardo Ferdani
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Shokeen M, Wadas TJ. The development of copper radiopharmaceuticals for imaging and therapy. Med Chem 2011; 7:413-29. [PMID: 21711219 PMCID: PMC8259694 DOI: 10.2174/157340611796799177] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2011] [Accepted: 05/08/2011] [Indexed: 12/11/2022]
Abstract
The increasing use of positron emission tomography in preclinical and clinical settings has widened the demand for radiopharmaceuticals with high specificity that can image biological phenomena in vivo. While many PET tracers have been developed from small organic molecules labeled with carbon-11 or fluorine-18, the short half-lives of these radionuclides preclude their incorporation into radiotracers, which can be used to image biological processes that are not induced immediately after system perturbation. Additionally, the continuing development of targeted agents, such as antibodies and nanoparticles, which undergo extended circulation, require that radionuclides with half-lives that are complimentary to the biological half-lives of these molecules be developed. Copper radionuclides have received considerable attention since they offer a variety of half-lives and decay energies and because the coordination chemistry of cooper and its role in biology is well understood. However, in addition to the radiometal chelate, a successful copper based radiopharmaceutical depends upon the chemical structure of the entire radiotracer, which may include a biologically important molecule and a chemical linker that can be used to deliver the copper radionuclide to a specific target and modulate its in vivo properties, respectively. This review discusses the development of copper radiopharmaceuticals and the importance of factors such as chemical structure on their pharmacokinetics in vivo.
Collapse
Affiliation(s)
- Monica Shokeen
- Division of Radiological Sciences, Washington University School of Medicine, Campus Box 8225, 510 S. Kingshighway Blvd., Saint Louis, MO 63110, USA
| | - Thaddeus J. Wadas
- Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC, 27157, USA
| |
Collapse
|
41
|
Silversides JD, Smith R, Archibald SJ. Challenges in chelating positron emitting copper isotopes: tailored synthesis of unsymmetric chelators to form ultra stable complexes. Dalton Trans 2011; 40:6289-97. [PMID: 21455520 DOI: 10.1039/c0dt01395a] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The synthesis of chelators that form high stability complexes with copper(II) isotopes and do not suffer from transchelation in vivo has been a goal for many chemists. Such chelators will facilitate the exploitation of the (64)Cu isotope (t(1/2) = 12.7 h, β(+) (19%); β(-) (39%); EC (41%)) for positron emission tomography imaging studies, which has a longer half life relative to the more commonly used (18)F (t(1/2) = 109.8 min) and (11)C (t(1/2) = 20.4 min) isotopes. One option is the CBTE2A chelator, which has been championed by Weisman, Wong and Anderson, and, more recently, alternate bifunctional chelator (BFC) versions have been synthesised. Improved synthetic methods are required for unsymmetric derivatisation of these chelators to allow more selective biomolecule attachment. This work investigates synthetic routes to form new unsymmetric chelating ligands via stepwise reaction of the bisaminal precursor, determines their X-ray structures and demonstrates cold copper(II) isotope complex formation.
Collapse
Affiliation(s)
- Jon D Silversides
- Department of Chemistry, The University of Hull, Cottingham Road, Hull, UK HU6 7RX
| | | | | |
Collapse
|
42
|
Bernier N, Costa J, Delgado R, Félix V, Royal G, Tripier R. trans-Methylpyridine cyclen versus cross-bridged trans-methylpyridine cyclen. Synthesis, acid-base and metal complexation studies (metal = Co2+, Cu2+, and Zn2+). Dalton Trans 2011; 40:4514-26. [PMID: 21409259 DOI: 10.1039/c0dt01191f] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The synthesis of the cross-bridged cyclen CRpy(2) {4,10-bis((pyridin-2-yl)methyl)-1,4,7,10-tetraazabicyclo[5.5.2]tetradecane}, a constrained analogue of the previously described trans-methylpyridine cyclen Cpy(2) is reported. The additional ethylene bridge confers to CRpy(2) proton-sponge type behaviour which was explored by NMR and potentiometric studies. Transition metal complexes have been synthesized (by complexation of both ligands with Co(2+), Cu(2+) and Zn(2+)) and characterized in solution and in the solid state. The single crystal X-ray structures of [CoCpy(2)](2+), [CuCpy(2)](2+) and [ZnCpy(2)](2+) complexes were determined. Stability constants of the complexes, including those of the cross-bridged derivative, were determined using potentiometric titration data and the kinetic inertness of the [CuCRpy(2)](2+) complex in an acidic medium (half-life values) was evaluated by spectrophotometry. The pre-organized structure of the cross-bridged ligand imposes an additional strain for the complexation leading to complexes with smaller thermodynamic stability in comparison with the related non-bridged ligand. The electrochemical study involving cyclic voltammetry underlines the importance of the ethylene cross-bridge on the redox properties of the transition metal complexes.
Collapse
Affiliation(s)
- Nicolas Bernier
- Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Av. da República, 2780-157, Oeiras, Portugal
| | | | | | | | | | | |
Collapse
|
43
|
Jin ZH, Furukawa T, Galibert M, Boturyn D, Coll JL, Fukumura T, Saga T, Dumy P, Fujibayashi Y. Noninvasive visualization and quantification of tumor αVβ3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4. Nucl Med Biol 2011; 38:529-40. [PMID: 21531290 DOI: 10.1016/j.nucmedbio.2010.11.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 11/01/2010] [Accepted: 11/11/2010] [Indexed: 11/27/2022]
Abstract
INTRODUCTION The α(V)β(3) integrin is a well-known transmembrane receptor involved in tumor invasion, angiogenesis and metastasis. Our aim was to evaluate a novel positron emission tomography (PET) probe, (64)Cu-cyclam-RAFT-c(-RGDfK-)(4), for noninvasive visualization and quantification of α(V)β(3) integrin expression. METHODS RAFT-c(-RGDfK-)(4), a tetrameric cyclic Arg-Gly-Asp (RGD)-based peptide, was conjugated with a bifunctional chelator, 1,4,8,11-tetraazacyclotetradecane (cyclam), radiolabeled with the positron emitter (64)Cu and evaluated in vitro by cell binding and competitive inhibition assays and in vivo by biodistribution and receptor blocking studies, and PET imaging. The following cell lines, human embryonic kidney HEK293(β(1)) [α(V)β(3)-negative] and HEK293(β(3)) [α(V)β(3)-overexpressing] and human glioblastoma U87MG [naturally expressing α(V)β(3)], together with their subcutaneous xenografts in athymic nude mice, were used for the present study. The expression levels of α(V)β(3) on these cell lines and tumor xenografts were analyzed by flow cytometry and sodium dodecyl sulfate-polyacrylamide gel electrophoresis/autoradiography, respectively. RESULTS (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) demonstrated the in vitro and in vivo specificity for the α(V)β(3) integrin and displayed rapid blood clearance, predominantly renal excretion and low uptake in nontumor tissues. Tumor uptake of (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) (3 h postinjection) in HEK293(β(3)) (high levels of α(V)β(3)), U87MG (moderate levels of α(V)β(3)) and HEK293(β(1)) (undetectable levels of α(V)β(3)) tumors was 9.35%±1.19%, 3.46%±0.45% and 1.18%±0.30% injected dose per gram, respectively, with a strong and positive correlation with the tumor α(V)β(3) expression levels (correlation coefficient=0.967; P<.0001). Positron emission tomographic images showed that α(V)β(3)-positive tumors were clearly visualized with high tumor-to-background contrast, and agreed well with the biodistribution results. CONCLUSION (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) exhibits potential for noninvasively quantifying α(V)β(3) expression.
Collapse
Affiliation(s)
- Zhao-Hui Jin
- Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Mu L, Honer M, Becaud J, Martic M, Schubiger PA, Ametamey SM, Stellfeld T, Graham K, Borkowski S, Lehmann L, Dinkelborg L, Srinivasan A. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 2011; 21:1864-71. [PMID: 20857927 DOI: 10.1021/bc100222u] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The gastrin-releasing peptide receptor (GRPR) is overexpressed on a number of human tumors and has been targeted with radiolabeled bombesin analogues for the diagnosis and therapy of these cancers. Seven bombesin analogues containing various linkers and peptide sequences were designed, synthesized, radiolabeled with (18)F, and characterized in vitro and in vivo as potential PET imaging agents. Binding studies displayed nanomolar binding affinities toward human GRPR for all synthesized bombesin analogues. Two high-affinity peptide candidates 6b (K(i) = 0.7 nM) and 7b (K(i) = 0.1 nM) were chosen for further in vivo evaluation. Both tracers revealed specific uptake in GRPR-expressing PC-3 tumors and the pancreas. Compared to [(18)F]6b, compound [(18)F]7b was characterized by superior tumor uptake, higher specificity of tracer uptake, and more favorable tumor-to-nontarget ratios. In vivo PET imaging allowed for the visualization of PC-3 tumor in nude mice suggesting that [(18)F]7b is a promising PET tracer candidate for the diagnosis of GRPR-positive tumors in humans.
Collapse
Affiliation(s)
- Linjing Mu
- Center for Radiopharmaceutical Sciences of ETH, PSI and USZ, Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Lattuada L, Barge A, Cravotto G, Giovenzana GB, Tei L. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents. Chem Soc Rev 2011; 40:3019-49. [DOI: 10.1039/c0cs00199f] [Citation(s) in RCA: 139] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
46
|
Li Z, Conti PS. Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev 2010; 62:1031-51. [PMID: 20854860 DOI: 10.1016/j.addr.2010.09.007] [Citation(s) in RCA: 144] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2010] [Revised: 09/11/2010] [Accepted: 09/13/2010] [Indexed: 12/13/2022]
Abstract
Molecular imaging is an emerging technology that allows the visualization of interactions between molecular probes and biological targets. Molecules that either direct or are subject to homeostatic controls in biological systems could be labeled with the appropriate radioisotopes for the quantitative measurement of selected molecular interactions during normal tissue homeostasis and again after perturbations of the normal state. In particular, positron emission tomography (PET) offers picomolar sensitivity and is a fully translational technique that requires specific probes radiolabeled with a usually short-lived positron-emitting radionuclide. PET has provided the capability of measuring biological processes at the molecular and metabolic levels in vivo by the detection of the gamma rays formed as a result of the annihilation of the positrons emitted. Despite the great wealth of information that such probes can provide, the potential of PET strongly depends on the availability of suitable PET radiotracers. However, the development of new imaging probes for PET is far from trivial and radiochemistry is a major limiting factor for the field of PET. In this review, we provided an overview of the most common chemical approaches for the synthesis of PET-labeled molecules and highlighted the most recent developments and trends. The discussed PET radionuclides include ¹¹C (t₁(/)₂=20.4min), ¹³N (t₁(/)₂=9.9min), ¹⁵O (t₁(/)₂=2min), ⁶⁸Ga (t₁(/)₂=68min), ¹⁸F (t₁(/)₂=109.8min), ⁶⁴Cu (t₁(/)₂=12.7h), and ¹²⁴I (t₁(/)₂=4.12d).
Collapse
|
47
|
|
48
|
Martin ME, Parameswarappa SG, O'Dorisio MS, Pigge FC, Schultz MK. A DOTA-peptide conjugate by copper-free click chemistry. Bioorg Med Chem Lett 2010; 20:4805-7. [PMID: 20630750 DOI: 10.1016/j.bmcl.2010.06.111] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2010] [Revised: 06/14/2010] [Accepted: 06/21/2010] [Indexed: 10/19/2022]
Abstract
Attachment of DOTA to a novel monofluoro-cyclooctyne facilitates bioconjugation to an azide-modified peptide via Cu-free click chemistry. The resulting conjugate was radiolabeled with (111)In to afford a potential targeted molecular imaging agent with high specific activity and an excellent radiochemical purity.
Collapse
Affiliation(s)
- Molly E Martin
- Department of Pediatrics, Carver College of Medicine, University of Iowa, 4235 MERF 375 Newton Road, Iowa City, IA 52242, USA
| | | | | | | | | |
Collapse
|
49
|
Becaud J, Mu L, Karramkam M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Lehmann L, Borkowski S, Berndorff D, Dinkelborg L, Srinivasan A, Smits R, Koksch B. Direct one-step 18F-labeling of peptides via nucleophilic aromatic substitution. Bioconjug Chem 2010; 20:2254-61. [PMID: 19921791 DOI: 10.1021/bc900240z] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Methods for the radiolabeling molecules of interest with [18F]-fluoride need to be rapid, convenient, and efficient. Numerous [18F]-labeled prosthetic groups, e.g., N-succinimidyl 4 [18F]-fluorobenzoate ([18F]-SFB), 4-azidophenacyl-[18F]-fluoride ([18F]-APF), and 1-(3-(2-[18F]fluoropyridin-3-yloxy)propyl)pyrrole-2,5-dione ([18F]-FpyMe), for conjugating to biomolecules have been developed. As the synthesis of these prosthetic groups usually requires multistep procedures, there is still a need for direct methods for the nucleophilic [18F]-fluorination of biomolecules. We report here on the development of a procedure based on the trimethylammonium (TMA) leaving group attached to an aromatic ring and activated with different electron-withdrawing groups (EWGs). A series of model compounds containing different electron-withdrawing substituents, a trimethylammonium leaving group, and carboxylic functionality for subsequent coupling to peptides were designed and synthesized. The optimal model compound, 2-cyano-4-(methoxycarbonyl)-N,N,N-trimethylbenzenaminium trifluoromethanesulfonate, was converted to carboxylic acid and coupled to peptides. The results of the one-step [18F]-fluorination of tetrapeptides and bombesin peptides show that the direct 18F-labeling of peptides is feasible under mild conditions and in good radiochemical yields.
Collapse
Affiliation(s)
- Jessica Becaud
- Center for Radiopharmaceutical Science of ETH, PSI and USZ, Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Nayak TK, Regino CAS, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010; 37:1368-76. [PMID: 20155263 DOI: 10.1007/s00259-009-1370-z] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2009] [Accepted: 12/16/2009] [Indexed: 01/11/2023]
Abstract
PURPOSE Cetuximab is a recombinant, human/mouse chimeric IgG(1) monoclonal antibody that binds to the epidermal growth factor receptor (EGFR/HER1). Cetuximab is approved for the treatment of patients with HER1-expressing metastatic colorectal cancer. Limitations in currently reported radiolabeled cetuximab for PET applications prompted the development of (86)Y-CHX-A''-DTPA-cetuximab as an alternative for imaging HER1-expressing cancer. (86)Y-CHX-A''-DTPA-cetuximab can also serve as a surrogate marker for (90)Y therapy. METHODS Bifunctional chelate, CHX-A''-DTPA was conjugated to cetuximab and radiolabeled with (86)Y. In vitro immunoreactivity was assessed in HER1-expressing A431 cells. In vivo biodistribution, PET imaging and noncompartmental pharmacokinetics were performed in mice bearing HER1-expressing human colorectal (LS-174T and HT29), prostate (PC-3 and DU145), ovarian (SKOV3) and pancreatic (SHAW) tumor xenografts. Receptor blockage was demonstrated by coinjection of either 0.1 or 0.2 mg cetuximab. RESULTS (86)Y-CHX-A''-DTPA-cetuximab was routinely prepared with a specific activity of 1.5-2 GBq/mg and in vitro cell-binding in the range 65-75%. Biodistribution and PET imaging studies demonstrated high HER1-specific tumor uptake of the radiotracer and clearance from nonspecific organs. In LS-174T tumor-bearing mice injected with (86)Y-CHX-A''-DTPA-cetuximab alone, (86)Y-CHX-A''-DTPA-cetuximab plus 0.1 mg cetuximab or 0.2 mg cetuximab, the tumor uptake values at 3 days were 29.3 +/- 4.2, 10.4 +/- 0.5 and 6.4 +/- 0.3%ID/g, respectively, demonstrating dose-dependent blockage of the target. Tumors were clearly visualized 1 day after injecting 3.8-4.0 MBq (86)Y-CHX-A''-DTPA-cetuximab. Quantitative PET revealed the highest tumor uptake in LS-174T (29.55 +/- 2.67%ID/cm(3)) and the lowest tumor uptake in PC-3 (15.92 +/- 1.55%ID/cm(3)) xenografts at 3 days after injection. Tumor uptake values quantified by PET were closely correlated (r (2) = 0.9, n = 18) with values determined by biodistribution studies. CONCLUSION This study demonstrated the feasibility of preparation of high specific activity (86)Y-CHX-A''-DTPA-cetuximab and its application for quantitative noninvasive PET imaging of HER1-expressing tumors. (86)Y-CHX-A''-DTPA-cetuximab offers an attractive alternative to previously labeled cetuximab for PET and further investigation for clinical translation is warranted.
Collapse
Affiliation(s)
- Tapan K Nayak
- Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
| | | | | | | | | | | | | | | |
Collapse
|